Article Information
History
- January 8, 2021.
Article Versions
- Version 1 (January 6, 2021 - 17:30).
- You are currently viewing Version 2 of this article (January 8, 2021 - 13:12).
- View Version 3, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Jiří Zahradník1,
- Shir Marciano1,
- Maya Shemesh1,
- Eyal Zoler1,
- Jeanne Chiaravalli2,
- Björn Meyer3,
- Orly Dym4,
- Nadav Elad5 and
- Gideon Schreiber1,6
- 1Department of Biomolecular Sciences, Weizmann Institute of Science, Rehovot 7610001, Israel
- 2Chemogenomic and Biological Screening Core Facility Institut Pasteur, 75724 Paris, France
- 3Viral Populations and Pathogenesis Unit CNRS UMR 3569 Institut Pasteur, 75724 Paris, France
- 4Department of Life Sciences Core Facilities, Weizmann Institute of Science, Rehovot 7610001, Israel
- 5Department of Chemical Research Support, Weizmann Institute of Science, Rehovot 7610001, Israel
- ↵6Corresponding author: gideon.schreiber{at}weizmann.ac.il
Posted January 08, 2021.
SARS-CoV-2 RBD in vitro evolution follows contagious mutation spread, yet generates an able infection inhibitor
